NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program
Key Highlights
- ➤NeuroOne (NMTC) secured its first pharmaceutical industry purchase order for StereoCED™.
- ➤Purchase order supports a Tier 1 global pharmaceutical company’s preclinical animal research program.
- ➤Large-animal research program is expected to commence early next year.
- ➤StereoCED™ is currently available for animal research and approved investigational clinical studies.
- ➤StereoCED™ is not approved or cleared for commercial use by any regulatory agency.
Expert Statements
David Wambeke, Chief Business Officer of NeuroOne
“We said we would complete development of StereoCED™ in fiscal Q4, and we delivered.”
David Wambeke, Chief Business Officer of NeuroOne
“With our first purchase order supporting a tier 1 global pharmaceutical company and StereoCED current availability for human investigational clinical studies, we are entering an exciting new phase.”
David Wambeke, Chief Business Officer of NeuroOne
“We believe StereoCED offers capabilities that competing drug delivery platforms do not, which positions NeuroOne to play an important role in the development of next-generation brain therapies.”
Major Commercial Milestone Represents Important Step Toward Potential Long-Term Collaborations with Global Pharmaceutical Companies
EDEN PRAIRIE, Minn., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it has secured its first pharmaceutical industry purchase order for the StereoCED™ Drug Delivery Platform to support a preclinical animal research program for a Tier 1 global pharmaceutical company.
Get started
Create a free account to read the full story.